Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of January 2018, with the report signed on January 18, 2018. The filing serves as a New Issue Announcement and Application for Quotation of Additional Securities under ASX Listing Rules. The registrant is a foreign private issuer based in Australia.
Key Financial Metrics and Capital Structure
The filing details a specific equity issuance event rather than providing comprehensive financial statements (revenue, profit, or cash flow).
- Securities Issued: 500,000 unlisted options (Class PBTAAA) issued under an Employee Incentive Scheme (ESOP).
- Consideration: Nil cash consideration.
- Terms: Exercise price of AUD$0.11; Expiry date of December 14, 2022.
- Existing Capital: 533,891,470 Fully Paid Ordinary Shares quoted on ASX.
- Outstanding Options: Total of 28,566,063 unlisted options across various classes (PBTAA through PBTAAA) with exercise prices ranging from AUD$0.07 to AUD$1.12.
Material Changes
The primary material change reported is the issuance of 500,000 new options under Rule 7.2 exceptions. Additionally, the filing notes the lapse of 1,200,000 PBTAS options, 1,000,000 PBTAB options, and 160,000 PBTAD options. The filing does not provide comparative financial data (e.g., revenue or profit changes) versus prior periods.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond standard regulatory disclosures. The purpose of the issue is explicitly stated as fulfilling obligations under the Employee Incentive Scheme and Consulting Agreements. The entity confirmed it is an eligible entity that obtained security holder approval under Rule 7.1A on November 17, 2017.
Investor Verification Checklist
- Verify the total number of outstanding options (28,566,063) and their respective exercise prices to assess potential dilution.
- Confirm the remaining placement capacity under ASX Rule 7.1 (80,083,721 securities) and Rule 7.1A (53,389,147 securities) as calculated in Annexure 1.
- Review the specific terms of the Employee Incentive Scheme to understand vesting conditions for the newly issued 500,000 options.
- Note that the filing does not provide revenue, profit, or cash flow data; investors should refer to the most recent Form 20-F or annual report for financial performance.